

To: 5.1.2e | 5.1.2e | 5.1.2e @rivm.nl]
Cc: 5.1.2e | 5.1.2e | 5.1.2e @rivm.nl]; 5.1.2e | 5.1.2e | 5.1.2e @rivm.nl]
From: 5.1.2e | 5.1.2e
Sent: Wed 1/20/2021 2:21:41 PM
Subject: FW: ECDC RT Report 20 January 2021 bericht ZA variant en vaccine efficacy
Received: Wed 1/20/2021 2:21:41 PM
[RoundTableReport_20210120.pdf](#)
[SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.pdf](#)

Hoi 5.1.2e

Ik stuur het RTR en een studie naar immuniteit in relatie tot de de SA-variant even door. Mogelijk meer kan op herinfecties met deze variant.

Voor het overleg over herinfecties vrijdag heb ik 5.1.2e en 5.1.2e 5.1.2e (in de CC) ook uitgenodigd.

Groet,

5.1.2e

Dag

Ter info onderstaande info uit het RTR van vandaag (20-01). Bijgevoegd het RTR en de genoemde studie:

A non-peer reviewed study on SARS-CoV-2 501Y.V2 / B.1.135 lineage shows, that combination of amino acid changes in 501Y.V2 variant virus confer complete resistance to neutralisation by several monoclonal antibodies, as well as reduced neutralisation or complete resistance to neutralisation by convalescent plasma and sera. These data add to growing evidence implicating substitution E484K (found in 501Y.V2) in escape from a broad array of antibodies. The results show that SARS-CoV-2 501Y.V2 lineage has effectively escaped neutralizing antibodies targeting an immunodominant, highly antigenic site in the receptor binding domain and in N-terminal domain of the spike protein. These results raise some concerns about whether the variant can increase the risk of reinfection or vaccine breakthrough infections.

Gr 5.1.2e

From: Duty EI 24/7 <support@ecdc.europa.eu>

Sent: woensdag 20 januari 2021 12:22

Subject: ECDR1 Report 26 January 2021

Dear colleague,

We are pleased to share with you the ECDC Round Table Report. This report summarizes the daily roundtable discussion

and provides update on threats detected and monitored by Epidemic Intelligence. This report contains information that might be sensitive or under verification. Its distribution is restricted to intended users only.

For further distribution, translation or copy of contents please contact support@ecdc.europa.eu.

Best regards,

5.1.2e

On behalf of
ECDC 24/7 duty team



European Centre for Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone +[39064644444](tel:+39064644444) 5.1.2e

www.ecdc.europa.eu

Follow ECDC on:



Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.